RxDoctor Payments Data

Michelle Corle

Family · Johnstown, PANPI 1033662770

Payments from drug & device makers

$13,090in general payments, 2019–2025

Across 663 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Pfizer$1K
  • Boston Scientific$657
  • AstraZeneca$614
  • Lilly USA, LLC$592
  • Novo Nordisk$589
  • plus $6K from 37 others

What the payments were for

  • Travel & lodging$1921%
  • Food & beverage$12,87898%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,090 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$10,845
Medicare patients
51
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$87,121
EliquisApixaban106$80,407
JardianceEmpagliflozin65$69,799
MounjaroTirzepatide47$51,147
XareltoRivaroxaban43$43,218
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$26,124
FarxigaDapagliflozin Propanediol29$24,579
Breo ElliptaFluticasone/Vilanterol41$22,671
TrulicityDulaglutide18$15,934
EntrestoSacubitril/Valsartan20$14,987
LinzessLinaclotide13$13,952
QuliptaAtogepant12$13,876
Advair HfaFluticasone Propion/Salmeterol32$12,825
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$11,155
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$10,358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$589$87,12182 claims
PfizerEliquis$1,026$80,407106 claims
Boehringer IngelheimJardiance$350$69,79965 claims
Lilly USA, LLCMounjaro, Trulicity$592$67,08165 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$472$59,153101 claims
Johnson & JohnsonXarelto$360$43,21843 claims
AbbVieLinzess, Qulipta, Synthroid$3,846$30,28693 claims
AstraZenecaFarxiga$614$24,57929 claims
NovartisEntresto$58$14,98720 claims
MerckDulera$122$4,06011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Johnstown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →